参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Prostate Cancer Version 1.2019-March 6,2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed.,2017).
3.Negoita S,Feuer EJ,Mariotto A,et al.Annual Report to the Nation on the Status of Cancer,part II: Recent changes in prostate cancer trends and disease characteristics.Cancer 2018.
4.Ke lly SP,Anderso n WF,Rosen berg PS,et al.Past,current,and future incidence rates and burden of metastatic prostate cancer in the United States.Eur Urol Focus 2017.
5.Fedewa SA,Ward EM,Brawley O, et al.Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States.JAMA Intern Med 2017, 177: 1040-1042.
6.Etzioni R,Gulati R.Recent trends in PSA testing and prostate cancer incidence: A look at context.JAMA Oncol 2016, 2: 955-956.
7.Fedewa SA,Ward EM,Brawley O, et al.Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States.JAMA Intern Med 2017, 177: 1040-1042.
8.Kearns JT,Holt SK,Wright JL,et al.PSA screening,prostate biopsy,and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.Cancer 2018.
9.Maurice MJ,Kim SP,Abouassaly R.Current status of prostate cancer diagnosis and management in the United States.JAMA Oncol 2016, 2: 1505-1507.
10.28.Epstein JI,Zelefsky MJ,Sjoberg DD,et al.A contemporary prostate cancer grading system: a validated alternative to the Gleason score.Eur Urol 2016, 69: 428-435.
11.Mathieu R,Moschini M,Beyer B,et al.Prognostic value of the new grade groups in prostate cancer: a multiinstitutional European validation study.Prostate Cancer Prostatic Dis 2017, 20: 197-202.
12.Hamdy FC,Donovan JL,Lane JA,et al.10-Year outcomes after monitoring,surgery,or radiotherapy for localized prostate cancer.N Engl J Med 2016, 375: 1415-1424.(https://www.daowen.com)
13.Pham KN,Cullen J,Hurwitz LM,et al.Prospective quality of life in men choosing active surveillance compared to those biopsied but not diagnosed with prostate cancer.J Urol 2016, 196: 392-398.
14.Godtman RA,Holmberg E,Khatami A,et al.Longterm results of active surveillance in the Goteborg randomized,population-based prostate cancer screening trial.Eur Urol 2016, 70: 760-766.
15.Yamamoto T,Musunuru B,Vesprini D,et al.Metastatic prostate cancer in men initially treated with active surveillance.J Urol 2016, 195: 1409-1414.
16.Yaxley JW,Coughlin GD,Chambers SK,et al.Robotassisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study.Lancet 2016, 388: 1057-1066.
17.Hannan R,Tumati V,Xie XJ,et al.Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multiinstitutional clinical trial.Eur J Cancer 2016, 59: 142-151.
18.Spratt DE,Soni PD,McLaughlin PW,et al.American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for highrisk prostate cancer.Brachytherapy 2017, 16: 1-12.
19.Krauss DJ,Ye H,Martinez AA,et al.Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction highdose-rate brachytherapy.Int J Radiat Oncol Biol Phys 2017, 97: 98-106.
20.Bolla M,Maingon P,Carrie C,et al.Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991.J Clin Oncol 2016, 34: 1748-1756.
21.Lawton CAF,Lin X,Hanks GE,et al.Duration of androgen deprivation in locally advanced prostate cancer: Longterm update of NRG Oncology RTOG 9202.Int J Radiat Oncol Biol Phys 2017, 98: 296-303.
22.Spratt DE,Yousefi K,Deheshi S,et al.Individual patientlevel metaanalysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease.J Clin Oncol 2017, 35: 1991-1998.
23.de Morree ES,Vogelzang NJ,Petrylak DP,et al.Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: A post hoc analysis of the mainsail study.JAMA Oncol 2017, 3: 68-75.